Literature DB >> 34430605

Clinical impact of craniopharyngioma classification based on location origin: a multicenter retrospective study.

Wenfu Hu1, Binghui Qiu1, Fen Mei1, Jian Mao1, Lizhi Zhou2, Fan Liu1, Jun Fan1, Yi Liu1, Ge Wen3, Songtao Qi1, Yun Bao1, Jun Pan1.   

Abstract

BACKGROUND: An assessment of the clinical impact for craniopharyngiomas (CPs) classification based on origin location has not been reported. The aim of this study was to determine the clinical impact of the site of tumor origin in primary CPs.
METHODS: Patients from six national institutions who had undergone resection for primary CP were enrolled. Based on the point of origin and surrounding membranous structures, the location of the tumor origin was labelled as Q, S, or T, where Type Q CPs originated below the diaphragmatic area; Type S CPs originated from Rathke's pouch precursor cells; and Type T CPs originated from the Rathke's pouch precursor cells located above the pars tuberalis. Clinical characteristics, surgical approach, and outcome were evaluated according to the location of the tumor origin.
RESULTS: Among the 529 patients with primary CP, symptoms, age, histopathology type, tumor size, the incidence of hydrocephalus, survival rates, and recurrence-free survival rates were significantly different among tumors originating in different locations. Patients with type T CPs had higher symptom rates of intracranial hypertension and hypothalamic dysfunction, while those with type Q CPs had higher rates of hormone deficits during pre-and post-operative management. Type S CPs were correlated with better outcomes and lower recurrence rates. The location of origin and primary therapy with survival and recurrence in CP were independent factors for survival and recurrence in multivariate analysis.
CONCLUSIONS: The identification of the different location of origin of CPs is of great significance in understanding the relationship between tumors and peripheral tissues. The origin of tumors effects the choice of surgical approach and prognosis. 2021 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Craniopharyngioma (CP); classification; origin location; outcome

Year:  2021        PMID: 34430605      PMCID: PMC8350632          DOI: 10.21037/atm-21-2924

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


Introduction

Although craniopharyngioma (CP) is a benign tumor, it is challenging to treat due to the nature of its location relation to peripheral structures (1). Surgical resection is the treatment of choice for CP, and the extent of resection plays a major role in the outcome of surgery. Performing complete resection at presentation offers an optimal choice for tumor control and potential cure with an acceptable morbidity rate (2-4). Hence, a suitable surgical approach can improve survival. The choice of operative approach for total resection should be determined according to the mode of tumor growth and as the site of origin of a tumor often has dense adhesions, locating this can predict likely difficulties to be encountered during surgery and aid in the selection of an appropriate surgical approach. Whilst this might lead to differences in the prognosis and recurrence, there have been few investigations to verify this (4,5), and the clinical significance of three different origin types of CP tumors has not yet been clarified. Hence, in this study, we aimed to determine the impact of tumor location origin on the surgical approach, survival, and tumor recurrence in patients undergoing resection of primary CP. We present the following article in accordance with the STROBE reporting checklist (available at https://dx.doi.org/10.21037/atm-21-2924).

Methods

Study cohort and clinicopathological variables

We included all patients who were histologically identified and underwent resection of CPs between March 1997 and December 2012 at six major neurosurgery centers. Patients who underwent surgery for recurrent tumors were excluded due to alterations in the anatomy of the tumor origin site during the first surgery making it difficult to precisely identify. Patients with incomplete records or who were lost to follow-up were also excluded to reduce the bias. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by ethics board of Nanfang Hospital, Southern Medical University (No.: NFEC201096). Individual consent for this retrospective analysis was waived.

Follow-up material and basic surgical approach

All patients underwent exhaustive preoperative and postoperative endocrine examinations involving the pituitary and hypothalamus (6-9). Visual evaluation included corrected and uncorrected visual acuities with visual field examinations in the Ophthalmologic department before and after surgery. All surgical records, image data, and videos were reviewed to help assess the extent of resection and tumor location. The approaches attempted for gross-total resection in this study included the frontal base interhemispheric, pterional, lateral ventricle, transcallosal, and transsphenoidal. The surgical approach was selected according to the origin of the tumor. The recurrence-free survival rate, total survival rate, imaging features, and pituitary hypothalamic functions were analyzed using long-term follow-up data. The outcome was divided into good and poor according to the system outlined in the study of Duff et al. as follows (10); good (alive, with functional vision, no major motor deficit in connection with the treatment or tumor progression, Karnofsky Performance Scale score of not less than 80, Katz grade of A, employability for adults at working age, school status of no more than 1 year behind the expected grade for young adults and children, no debilitating emotional or psychological problems), or poor (all patients not meeting the “good” criteria).

Histopathological evaluation and definition of tumor location

The diagnosis of CP in all patients was confirmed by histology. Preoperative imaging was reviewed by Dr. Jun Pan and Dr. Yun Bao in each case to ascertain the location of the tumor origin for determining the potential for study inclusion in a blinded fashion. If consensus could not be reached, Dr. Songtao Qi was assigned to make the final decision. The pituitary stalk (PS) was divided into four segments in accordance with the folds of the arachnoid sleeve around the pituitary stalk (ASPS) (11). Accordingly, we categorized the tumors into three types (3,5). The origin site of type Q CP is located below the diaphragmatic area and the extra-arachnoidal, intra-arachnoidal, and sub-arachnoidal segments of the PS as situated above the tumor. The dura mater, arachnoid, pituitary stalk and the third ventricle floor (3VF) were located above the tumor. These tumors are surrounded by the suprasellar arachnoid and dura mater. Type Q tumors usually demonstrate marked enlargement of the pituitary fossa and a large rounded and symmetrical extension to the suprasellar space. Type S CPs originate from Rathke’s pouch precursor cells, that are to the extra- and intra-arachnoidal segments of the PS, and the main body of these tumors is in the suprasellar arachnoid around the PS. The arachnoid and the 3VF are located above the tumor, the PS is located beside the tumor, the dura mater is below the tumor. Although type S tumors can grow into one or various subarachnoid cisterns, and/or into the pituitary fossa, they tend not to expand the pituitary fossa, and the diaphragm, basal arachnoid, and pituitary can be found below the tumor. If the tumor grows upward, the third ventricle floor can be pushed up. Type T CPs originate from the Rathke’s pouch precursor cells, which are at the top of pars the tuberalis. 3VF is pushed up, and the third ventricle cavity is often occupied by the tumor. The PS, arachnoidal sleeve, and basal arachnoid are beneath type T tumors ().
Figure 1

Classification of CPs based on origin location. (A) Several possible sites of tumor origin are indicated as Q (black dots), S (yellow dots), and T (red dots); (B1) preoperative contrast-enhanced MR images of type Q CP; (B2) the relationship between type Q tumors and surrounding structures; (C1) preoperative contrast-enhanced MR images of type S CP; (C2) the relationship between type S tumors and surrounding structures; (D1) preoperative contrast-enhanced MR images of type T CP; (D2) the relationship between type T tumors and surrounding structures. White dots represent the origin point, green lines represent the arachnoid membrane, blue lines represent the dura mater, and violet lines represent the ependyma.

Classification of CPs based on origin location. (A) Several possible sites of tumor origin are indicated as Q (black dots), S (yellow dots), and T (red dots); (B1) preoperative contrast-enhanced MR images of type Q CP; (B2) the relationship between type Q tumors and surrounding structures; (C1) preoperative contrast-enhanced MR images of type S CP; (C2) the relationship between type S tumors and surrounding structures; (D1) preoperative contrast-enhanced MR images of type T CP; (D2) the relationship between type T tumors and surrounding structures. White dots represent the origin point, green lines represent the arachnoid membrane, blue lines represent the dura mater, and violet lines represent the ependyma. The main differences in the tumors originating from the different sites are as follows: type Q tumors are found below the diaphragm, while type S are located on the extra-arachnoidal and intra-arachnoidal segments of the stalk, and type T tumors are situated at the pars tuberalis.

Statistical analysis

Statistical analysis was performed using IBM SPSS software (version 26.0, SPSS Inc., Chicago, IL, USA). Medians and ranges of continuous variables were compared using the Mann-Whitney U test and categorical variables were compared using Fisher’s exact test or Pearson’s chi-squared test. The overall survival (OS) was calculated based on the time from surgery until the last follow-up or death. Survival curves were generated using the Kaplan-Meier method and were compared by the log-rank test, and Cox regression analysis was performed to explore possible determinants of outcomes. The value for significance was set at P≤0.05.

Results

Clinical characteristics

We excluded 213 patients with recurrent tumors and/or radiotherapy and 19 patients with incomplete data or who were lost to follow-up. A total of 529 patients were enrolled from six national institutions. Of these, 209 patients were treated at Nanfang Hospital of Southern Medical University, 87 at the Fuzhou General Hospital of Nanjing Military Area Command, 73 at the Affiliated Hospital of Southwest Medical University, 59 at the First Affiliated Hospital of Fujian Medical University, 51 at the General Hospital of Ningxia Medical University, and 50 at the First Affiliated Hospital of Suzhou University. The median age of patients with CP was 23 years (range, 2–72 years), and 329 (62.2%) were men. There were 220 (41.6%) children and 309 (58.4%) adults when the tumor was detected. The median follow-up period was 83.0 months (range, 28–236 months) excluding the patients who died, who numbered 86 (16.3%) at the time of analysis ().
Table 1

Preoperative clinical characteristics of patients, stratified according to growth pattern types

ParameterType Q (n=142)Type S (n=115)Type T (n=272)Total (n=529)P value
Age at diagnosis
   Mean15.18±14.9634.90±18.9729.30±19.8926.73±19.86<0.001
   Range2–603–672–722–72
   Children, ≤14 yrs n (%)93 (65.5)24 (20.9)103 (37.9)220 (41.6)<0.001
   Adults, >14 yrs n (%)49 (34.5)91 (79.1)169 (62.1)309 (58.4)
Sex, n (%)
   Male93 (62.7)63 (55.7)173 (64.7)329 (62.2)0.168
   Female49 (37.3)52 (44.3)99 (35.3)200 (37.8)
Tumor size (cm)3.7±1.33.9±1.03.6±1.03.7±1.10.028
Follow-up (months)
   Mean106.8±48.0102.8±38.4100.0±43.8102.4±43.90.325
   Range17–23656–1963–2323–236
Hydrocephalus, n (%)
   None128 (90.1)98 (85.2)139 (51.1)365 (69.0)<0.001
   Yes14 (9.9)17 (14.8)133 (48.9)164 (31.0)
Tumor consistency, n (%)
   Solid18 (12.7)15 (13.1)36 (14.0)71 (13.4)0.695
   Mixed93 (65.5)77 (66.9)164 (60.3)334 (63.1)
   Cystic31 (21.8)23 (20.0)70 (25.7)124 (23.4)
Pathology, n (%)
   Adamantinomatous142 (100.0)102 (88.7)235 (86.4)479 (90.5)<0.001
   Papillary0 (0.0)13 (11.3)37 (13.6)50 (9.5)

QST classification and histopathological features

A total of 142 patients (26.8%) had type Q tumors, 115 (21.7%) had type S tumors, and 272 (51.4%) had type T tumors, and there were significant differences in the pathological subtypes among the three different types of tumors (P<0.001). The proportion of patients with adamantinomatous CP (ACP) was 100% (142/142), 88.7% (102/115), and 86.4% (235/272) among patients with types Q, S, and T tumors, respectively ().

Symptoms and signs

The location of the tumor origin and the main symptoms in patients with CP are summarized in . The tumor location was inferred according to the protocol described above, and the most common symptoms were headache, reduced vision, reduced visual field, and growth retardation. There were significant differences in the frequency of symptoms including headache, nausea or vomiting, diplopia, reduced vision, reduced visual field, seizures, loss of appetite, polyuria, growth retardation, weight gain, altered personality, memory impairment, concentration impairment, and reduced consciousness among the three tumor types.
Table 2

Presenting symptoms in craniopharyngioma, stratified according to growth pattern types

Symptoms (No.)Type Q (n=142)Type S (n=115)Type T (n=272)Total (n=529)P value
Headache57 (40.1)39 (34.0)162 (59.6)258 (48.8)<0.001
Nausea or vomiting9 (6.3)14 (12.2)89 (32.7)112 (21.2)<0.001
Diplopia32 (22.5)13 (11.3)10 (3.7)55 (10.4)<0.001
Reduced vision75 (52.8)75 (65.2)98 (36.0)248 (46.9)<0.001
Reduced visual field47 (33.1)63 (54.8)80 (29.4)190 (35.9)<0.001
Seizures5 (3.5)4 (3.5)8 (2.9)17 (3.2)<0.001
Loss of appetite10 (7.0)8 (7.0)8 (2.9)26 (4.9)<0.001
Weight loss4 (2.8)3 (2.6)8 (2.9)15 (2.8)0.984
Polyuria17 (12.0)6 (5.2)41 (15.1)64 (12.1)0.025
Growth retardation*78 (83.9)9 (37.5)46 (44.6)133 (60.5)<0.001
Weight gain5 (3.5)4 (3.5)34 (12.5)43 (8.1)0.001
Insomnia5 (3.5)0 (0.0)10 (3.7)15 (2.8)0.117
Altered personality1 (0.7)2 (1.7)10 (3.7)13 (2.5)0.008
Memory impairment5 (3.5)4 (3.5)30 (11.0)39 (7.4)0.004
Concentration impairment1 (0.7)4 (3.5)26 (9.6)31 (5.9)0.001
Reduced consciousness0 (0.0)4 (3.5)20 (7.4)24 (4.5)0.002

*, only in age ≤14 years group, n=220 (type Q =93, type S =24, type T =103).

*, only in age ≤14 years group, n=220 (type Q =93, type S =24, type T =103).

Treatment and surgical approach

Of the 529 patients, 403 (76.2%) were treated with gross total resection (GTR), 81 (15.3%) with subtotal resection (STR) without radiation therapy (RT), and 45 (8.5%) with STR with RT. Details of the surgical procedures are summarized in . The results showed significant differences in the surgical approach among the three different types of tumors (P<0.001).
Table 3

Presenting symptoms and surgical outcome in craniopharyngioma, stratified according to growth pattern type

ParameterType Q (n=142)Type S (n=115)Type T (n=272)Total (n=529)P value
Preoperative Pituitary dysfunction axes, n (%)
   0 axis4 (2.8)51 (44.3)72 (26.5)127 (24.0)<0.001
   1–2 axes35 (24.6)44 (38.3)130 (47.8)209 (39.5)
   3–4 axes103 (72.5)20 (17.4)70 (25.7)193 (36.5)
   Preoperative polyuria17 (12.0)6 (5.2)41 (15.1)64 (12.1)0.025
Postoperative pituitary dysfunction axes, n (%)
   0 axis1 (0.01)31 (27.0)51 (18.6)83 (15.7)<0.001
   1–2 axes22 (15.5)57 (49.6)121 (44.5)200 (37.8)
   3–4 axes119 (83.8)27 (23.5)100 (36.8)246 (46.5)
   Postoperative polyuria82 (57.7)47 (40.8)137 (50.4)266 (50.3)0.027
Surgical approach, n (%)
   Frontal base interhemispheric50 (35.2)25 (21.7)161 (59.2)236 (44.6)<0.001
   Pterion54 (38.0)73 (63.5)69 (25.4)196 (37.1)
   Transsphenoidal38 (26.8)7 (6.1)6 (2.2)51 (9.6)
   Lateral ventricle0 (0.0)2 (1.7)4 (1.5)6 (1.1)
   Transcallosal0 (0.0)8 (7.0)32 (11.8)40 (7.6)
Functional outcome, n (%)
   Good121 (85.2)103 (89.6)209 (76.8)433 (81.9)0.006
   Poor21 (14.8)12 (10.4)63 (23.2)96 (18.1)

Pituitary function and functional outcome

The cumulative probability for each deficit in all patients is shown in . There were significant differences in the number of pituitary axes with insufficiencies (0 axes, 1–2 axes, and 3–4 axes) among types Q, S, and T tumors at presentation and after surgery (P< 0.001). Of the remaining 336 patients, new anterior hypopituitarism occurred in 94 (17.8%), with at least one intact axis preoperatively. The overall clinical outcome was good and poor in 81.9% and 18.1% of patients, respectively, and final functional outcomes are shown in . Patients with type T CPs had a worse outcome than those with type S and type Q CPs ().

Recurrent factors for patients with CP

Among the 529 patients who underwent surgery, 136 were found to have tumor recurrence during follow up and the overall recurrence rate was 25.7%. The median recurrence time was 23 months (range, 1–98 months). Multivariate analysis was performed to identify the recurrent factors and survival factors for patients with CP, and we selected seven potential candidate factors for analysis including age (>14/≤14 y), sex (male/female), origin location of the tumor (Q, S, and T), primary therapy (GTR/STR/STR + RT), pathology (ACP/PCP), calcification status (big/small/no), and size status (>5/≤5 cm). The recurrence rate was affected by the size (P=0.023), primary therapy (P<0.001), and origin location (P<0.001) in the univariate analyses, and the primary therapy [P<0.001 B=1.137 Exp (B) =3.116, CI (2.568–3.781)], size [P=0.001 B=0.763 Exp (B) =2.144, CI (1.381–3.329)], and origin location [P<0.001 B=0.396 Exp (B) =1.485, CI (1.194–1.847)] were factors for recurrence in the multivariate analysis. The recurrence rate was not affected by age (P=0.082), sex (P=0.343), pathology (P=0.694), and calcification status (P=0.615) in the univariate analyses. The recurrence rate after resection was significantly lower for type S tumors (13/115, 11.3%) than for type Q (P=0.002), and type T tumors (P<0.001). Kaplan-Meier curves showed that the classification of tumors effectively stratified patient recurrence (). Recurrences appeared in 39 of 403 patients (9.7%) after total resection, in 77 of 81 patients (95.1%) after incomplete resection, and in 20 of 45 patients (44.4%) in incomplete resection plus radiotherapy. GTR was associated with a lower recurrence rate than STR (P<0.001) or STR with RT (P<0.001), and STR with RT was also associated with a lower recurrence rate than STR without RT (P<0.001). Kaplan-Meier curves showed that the classification of tumors effectively stratified patient recurrence ().
Figure 2

Graph depicting survival times in patients. All P values are based on log-rank test. (A) The image is related to the recurrence-free survival rate based on tumor origin location; (B) the image is related to the recurrence-free survival rate based on treatment modality; (C) the image is related to the overall-free survival rate based on tumor origin location; (D) the image is related to the overall-free survival rate based on treatment modality in Type T CP. GTR, gross total removal; STR, subtotal removal; RT, radiotherapy.

Graph depicting survival times in patients. All P values are based on log-rank test. (A) The image is related to the recurrence-free survival rate based on tumor origin location; (B) the image is related to the recurrence-free survival rate based on treatment modality; (C) the image is related to the overall-free survival rate based on tumor origin location; (D) the image is related to the overall-free survival rate based on treatment modality in Type T CP. GTR, gross total removal; STR, subtotal removal; RT, radiotherapy.

Survival factors for patients with CP

The total OS rate was affected by the primary therapy (P<0.001), origin location (P=0.013), and calcification (P=0.036) in the univariate analyses. The primary therapy [P<0.001 B=0.795 Exp (B) =2.215, CI (1.684–2.914)] and the origin location of the tumor [P=0.011 B=0.351 Exp (B) =1.420 CI, (1.085–1.859)] were factors for OS in the multivariate analysis. The total OS was lower in type T participants than in type Q (P=0.026) and type S (P=0.020) tumors. Kaplan–Meier curves showed that the classification of tumors effectively stratified patient prognosis (). The total OS was higher in GTR tumors than in STR (P<0.001) and STR with RT (P<0.001) tumors, and was not significantly different between STR and STR with RT tumors (). The main reasons for the 86 deaths in our study cohort were tumor progression, hypothalamic-pituitary dysfunction, and intracerebral vascular complications.

Discussion

CP is a benign tumor that arises from Rathke’s pouch and accounts for 1–4% of all brain tumors, and the overall incidence of CP is 0.13 per 100,000 person years (12,13). Surgical resection is the first choice for CP followed Yaşargil’s view (14). CPs are clinically relevant tumors of the sellar region (15). The management of patients with CP is complex and has attracted the attention of many researchers in different fields. To improve the understanding and outcome of CP, several classifications have been put forward including those based on their relationship with the diaphragm or stalk (14), tumor extension (16), endoscopic views of the infundibular region (17,18), and the degree of hypothalamic involvement (19). However, as it is difficult to classify large tumors according to the aforementioned classifications, and all primary CPs were classified based on the location of their origin in the present study. Although CPs are benign tumors, they are likely to involve the hypothalamic-pituitary axis and surrounding structures, which may limit surgical options to partial resection or lead to severe postoperative complications after total resection, especially severe hypothalamic reactions. To ensure safe surgical resection and avoid severe hypothalamic injury, understanding the pattern of gliosis is essential (2-4,11). The classification based on the origin of the tumor details the relationship of the surrounding structures to CPs and purports to predict and identify the intraoperative anatomical stratification. At the same time, it is not easy to expose the origin of CPs as the lesions have circumferential adhesions with surrounding structures, and the exposure of this area is a priority factor in the choice of surgical approach (20,21). According to the classification based on the location of the origin point and the relationship between the tumor and arachnoid structures (11), CPs can be divided into three types (5): type Q, type S, and type T. The location of origin of type Q tumors is below the diaphragm, type S is on the intra-arachnoidal and extra-arachnoidal segment of the stalk, and type T is in the pars tuberalis and sub-arachnoidal space. The key differences between type Q and type S/T are the presence of an enlarged pituitary fossa or whether the tumor is above the diaphragm. The main difference between type S and type T tumors is that the PS sits beside or at the bottom of the tumor, where the tumor extends into the subarachnoid space or the third ventricle, and whether the arachnoid is separated from the tuberoinfundibular and the tumor. In this study, we analyzed the influence of the location of the tumors origin on clinical characteristics, functional outcome, long-term survival, and recurrence-free survival in patients with primary CP. Our findings show the classification of CP according to the location of tumor origin effectively stratifies the prognosis of patients after undergoing curative resection of the tumor and that hypothalamus involvement is correlated with a higher OS rate (22). Type T tumors were strongly correlated with a higher incidence of hypothalamus involvement, resulting in a worse functional outcome and worse survival rate compared to patients with type Q and S tumors. Significant endocrine dysfunction is seen in most patients with CP, and in this study, we found that pituitary dysfunction in CP was largely related to the location of its origin point. It is common to find three or more hormone deficits in patients with type Q tumors, which might be due to the direct effect of the pituitary on tumor compression and inflammation (23). Endocrine replacement after GTR also offers a chance of cure in type Q tumors. As Type S tumors mainly grow in the subarachnoid space, which usually has a mild or moderate effect on the PS and 3VF, pituitary dysfunction in patients is usually not serious. Type T tumors usually extend to the 3VF and occupy the space of the third ventricle, resulting in hypothalamus damage. Owing to this, hypothalamic-pituitary dysfunction occurs frequently in this tumor type. In addition, we found that the symptoms, age, histopathology type, tumor size, and incidence of hydrocephalus were significantly different in the different types of tumors. Patients with type Q tumors were more likely to be younger compared to those with type S and T tumors. Several studies have described the symptoms of CPs (7,24,25), which include headache, nausea, vomiting, and symptoms related to hypothalamic function. These symptoms were more frequently observed in patients with type T tumors, which may be associated with intracranial hypertension. Memory deficits, behavioral abnormalities, and psychosocial impairment frequently occur early after the diagnosis of CP (8,26), and were especially seen in patients with type T CP in the present study, while reduced vision and visual field symptoms were more frequently observed in patients with type S and Q tumors than in those with type T tumors. As some authors have reported cases in which an erroneous classification of the type of CPs has resulted in an incorrect surgical approach (15,27,28), it is particularly important to consider the classification of the tumor based on its origin site (29), before surgery. The initial site of the tumor is usually the closest to the surrounding tissue, and the relationship between the tumor and the surrounding tissue (such as the hypothalamus) differs in different tumor types. The transsphenoidal approach is the most appropriate corridor to treat some types of Q tumors, as it avoids injury to the optic chiasm and third ventricle. The continuity of the 3VF-stalk-pituitary gland can be well protected in type S tumors via extra-axial approaches, while for type T tumors, if the upper edge of the tumor exceeds the mass intermedia, the trans-lamina terminalis approach can be selected to allow for additional exposure of the tumor. In addition, the classification of CP according to its site of origin can predict the adherent point and possible difficulties to during the course of the surgery. It is also important to predict the risk of CP adherence to the hypothalamus (29). Type T tumors are a strong predictor of adherence to the hypothalamus because of their origin point and radical resection becomes highly challenging because of their tenacious adherence to the infundibulo-tuberal region and the hypothalamus. Radical resection of type S tumors is easier than the other two tumor types, as well as a Grade V tumor in the classification system based on vertical extension (16), and the arachnoid between the tumor and 3VF should be a reliable boundary. Recently, progress in molecular biology has unravelled creative, potentially druggable molecular pathways in CPs that provide new prospective therapeutic options. The treatment of ACP with vismodegib, a sonic hedgehog pathway inhibitor, results in a substantial reduction in median survival in murine models and further research is needed to effectively translate these laboratory findings to clinical settings (30). BRAF inhibitors have been demonstrated to show effectiveness against BRAF-mutated papillary CP. Related drugs are already in clinical trials, but are currently only used for recurrent CPs (31,32).

Limitations

The limitations of this study include its retrospective nature and associated biases. However, CPs are relatively rare, and the study is one of the largest series to analyze the tumor. Moreover, the current data were obtained from six high-volume centers in the East, South, West, and North of China. The proposed definitions of origin location offer a simple and reliable method to evaluate the prognosis of patients with CP.

Conclusions

Identification of the tumor origin site is crucial in the management of primary CP. The classification of primary CP into Q, S, and T tumors provides a useful tool for selecting the surgical approach and predicting its outcome. The article’s supplementary files as
  32 in total

Review 1.  Intraventricular craniopharyngioma: its characteristics in magnetic resonance imaging and successful total removal.

Authors:  T Fukushima; K Hirakawa; M Kimura; M Tomonaga
Journal:  Surg Neurol       Date:  1990-01

2.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline.

Authors:  Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2011-06       Impact factor: 5.958

Review 3.  Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement.

Authors:  Stéphanie Puget; Matthew Garnett; Alison Wray; Jacques Grill; Jean-Louis Habrand; Nathalie Bodaert; Michel Zerah; Mercia Bezerra; Dominique Renier; Alain Pierre-Kahn; Christian Sainte-Rose
Journal:  J Neurosurg       Date:  2007-01       Impact factor: 5.115

4.  Acute presentation of craniopharyngioma in children and adults in a Danish national cohort.

Authors:  E H Nielsen; J O Jørgensen; P Bjerre; M Andersen; C Andersen; U Feldt-Rasmussen; L Poulsgaard; L Ø Kristensen; J Astrup; J Jørgensen; P Laurberg
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

Review 5.  Childhood craniopharyngioma. Recent advances in diagnosis, treatment and follow-up.

Authors:  Hermann L Muller
Journal:  Horm Res       Date:  2008-01-21

6.  Craniopharyngioma in adults.

Authors:  Flavius Zoicas; Christof Schöfl
Journal:  Front Endocrinol (Lausanne)       Date:  2012-03-29       Impact factor: 5.555

7.  Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.

Authors:  Priscilla K Brastianos; Amaro Taylor-Weiner; Peter E Manley; Robert T Jones; Dora Dias-Santagata; Aaron R Thorner; Michael S Lawrence; Fausto J Rodriguez; Lindsay A Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L Calicchio; Hart G W Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B Storm; John Y K Lee; James N Palmer; Nithin D Adappa; R Michael Scott; Ian F Dunn; Edward R Laws; Chip Stewart; Keith L Ligon; Mai P Hoang; Paul Van Hummelen; William C Hahn; David N Louis; Adam C Resnick; Mark W Kieran; Gad Getz; Sandro Santagata
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 38.330

8.  Pathological and Topographical Classification of Craniopharyngiomas: A Literature Review.

Authors:  James Lubuulwa; Ting Lei
Journal:  J Neurol Surg Rep       Date:  2016-07

9.  SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.

Authors:  G Carreno; J K R Boult; J Apps; J M Gonzalez-Meljem; S Haston; R Guiho; C Stache; L S Danielson; A Koers; L M Smith; A Virasami; L Panousopoulos; M Buchfelder; T S Jacques; L Chesler; S P Robinson; J P Martinez-Barbera
Journal:  Endocr Relat Cancer       Date:  2019-03       Impact factor: 5.678

10.  Value of magnetic resonance imaging in predicting BRAF mutation in craniopharyngiomas.

Authors:  Mario Giordano; Ismail Zaed
Journal:  Transl Cancer Res       Date:  2019-03       Impact factor: 1.241

View more
  3 in total

Review 1.  Update on management of craniopharyngiomas.

Authors:  Fraser Henderson; Theodore H Schwartz
Journal:  J Neurooncol       Date:  2021-11-22       Impact factor: 4.130

2.  Clinical Features of Craniopharyngioma With Tumoral Hemorrhage: A Retrospective Case-Controlled Study.

Authors:  Yusi Chen; Feng Hu; Junwen Wang; Kuan Huang; Weihua Liu; Yutang Tan; Kai Zhao; Qungen Xiao; Ting Lei; Kai Shu
Journal:  Front Surg       Date:  2022-03-14

3.  Erratum to clinical impact of craniopharyngioma classification based on location origin: a multicenter retrospective study.

Authors: 
Journal:  Ann Transl Med       Date:  2022-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.